3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase NA
2
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
50
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Recurrence
9
Burkitt Lymphoma
7
Neoplasms, Plasma Cell
5
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma
5
Immunoglobulin Light-chain Amyloidosis
5
Hodgkin Disease
4
Lymphoma, T-Cell
3
Lymphoma, Non-Hodgkin
3
Lymphoma, B-Cell
3
Leukemia
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Oligodendroglioma
2
Neoplasms
2
Neoplasm Metastasis
2
Mesothelioma
2
Lymphoma, T-Cell, Cutaneous
2
Leukemia, Myeloid, Acute
2
Leukemia, Hairy Cell
2
Leukemia, Biphenotypic, Acute
2
Hematologic Neoplasms
2
Glioblastoma
2
Blastic Plasmacytoid Dendritic Cell Neoplasm
2
Astrocytoma
2
Amyloidosis
2
Waldenstrom Macroglobulinemia
1
Vascular Diseases
1
Uveal Melanoma
1
Interventions
Cytarabine
11
Cyclophosphamide
10
Filgrastim
9
Etoposide
8
fludarabine phosphate
6
Vorinostat
6
Tacrolimus
6
Peripheral Blood Stem Cell Transplantation
6
Imatinib Mesylate
6
Dasatinib
6
Carboplatin
5
tipifarnib
4
sargramostim
4
Topotecan
4
Sirolimus
4
Bortezomib
4
tanespimycin
3
fludarabine
3
alvocidib
3
Whole-Body Irradiation
3
Sorafenib
3
Flow Cytometry
3
Doxorubicin
3
Decitabine
3
Busulfan
3
Antilymphocyte Serum
3
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
3
laromustine
2
entinostat
2
bryostatin 1
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Blast Crisis
×
Calcium Dobesilate
×
Clear all
NCT01204164
2016-05-06
TG02-101
Tragara Pharmaceuticals, Inc.
Phase 1
Completed
120 enrolled